Stockwinners Market Radar for June 13, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

12:21 EDT Novo Nordisk announces results from real-world studies of GLP-1 RAs and Ozempic - Novo Nordisk announced results from two real-world studies: EXPERT, which confirms the efficacy Ozempic demonstrated in the SUSTAIN clinical trial program, and PATHWAY, which supports recommendations in clinical guidelines by showing that initiation of a GLP-1 receptor agonist, or "GLP-1 RA," helps people with type 2 diabetes reach their blood sugar goals while also losing weight. These studies, which analysed data from US databases, were presented during the American Diabetes Association 80th Scientific Sessions. The EXPERT study showed that a switch to Ozempic from another GLP-1 RA in people with type 2 diabetes was associated with statistically significant reductions in blood sugar and weight, independent of the previous GLP-1 RA used. After 6 months, the study showed HbA1c reductions of 2.2% for people with HbA1c levels above 9% at baseline and HbA1c reductions of 1.1% for those with HbA1c levels above 7% at baseline. These reductions were sustained after 12 months. Average weight loss of 2.2 kg was observed at 6 months, but was more pronounced with 3.5 kg at 12 months, for all participants. A second real-world study, PATHWAY, pointed to the increased effectiveness of the GLP-1 RA class compared with other oral antidiabetic drugs or insulin in people with type 2 diabetes on two oral antidiabetic drugs requiring treatment intensification. Ozempic was not one of the GLP-1 RA treatments given at intensification because the study data were collated before Ozempic was fully established on the U.S. market.